Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

ORMP READ THE FULL ORMP RESEARCH REPORT Planning Spin-off / IPO of JV Company Oramed Pharmaceuticals (NASDAQ:ORMP) formed a JV with Hefei Tianhui Biotech (HTIT), OraTech Pharmaceuticals, which is a ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

As for stock performance, Viking won there too in the early part of last year. The stock surged 121% in one trading session ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...

MONTREAL and CHARLOTTE, N.C. - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a pharmaceutical company with a market capitalization of $149 million and showing strong momentum with a 47% price return ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did not approve its lead investigational product, Cardamyst. The nasal spray is ...